Morgan Stanley maintains a "overweight" rating on GUSHENGTANG(02273) with a target price of 62 Hong Kong dollars.

15:30 12/03/2025

Currently, private hospitals are not required to participate in volume-based procurement. The company expects the group to achieve a revenue growth of over 20% this year, with a profit increase of over 25%.

Morgan Stanley released a research report stating that they are maintaining a "buy" rating for GUSHENGTANG (02273) with a target price of 62 Hong Kong dollars. Currently, private hospitals are not required to participate in volume-based procurement. The bank expects the group to achieve revenue growth of over 20% this year, with profit growth expected to be over 25%.

HAO WEN HLDGS (08019) Enters into a Supplementary Memorandum of Understanding with Chengmai Junli

ZJ UNITED INV (08366): Fu Enming appointed as authorized representative

YU TAK INT'L (08048) announced its mid-year performance for 2025, with a net loss attributable to shareholders of HK$1.049 million, a year-on-year decrease of 83.26%.

HAO WEN HLDGS (08019) Enters into a Supplementary Memorandum of Understanding with Chengmai Junli

ZJ UNITED INV (08366): Fu Enming appointed as authorized representative

YU TAK INT'L (08048) announced its mid-year performance for 2025, with a net loss attributable to shareholders of HK$1.049 million, a year-on-year decrease of 83.26%.